Next Generation Sequencing Facilitates Quantitative Analysis of Human Bladder Smooth Muscle Cell Line Underwent Polo like kinase-1 inhibitor TAK960

Polo-like kinases, commonly abbreviated to PLK, are a family of serine/threonine kinases that are highly conserved across species and play a critical role in regulating various cellular processes. Specifically, PLKs are involved in the regulation of smooth muscle cell proliferation and contraction. Smooth muscle cells are essential components of numerous organs, including the bladder, that are integral to the functioning of the lower urinary tract system (LUTS). The prevalence of LUTS is high, with millions of individuals worldwide suffering from this clinical syndrome, which presents with symptoms such as voiding difficulties, increased frequency, and nocturia. Although the precise pathophysiology of LUTS is complex and multifaceted, it is believed that abnormalities in smooth muscle function and urinary cell proliferation contribute significantly to its onset and progression. Therefore, targeting PLK may represent a promising therapeutic approach for LUTS, particularly for conditions such as bladder outlet obstruction (BOO), overactive bladder (OAB), and cystitis. In this study, bladder smooth muscle cells were treated with TAK960 for 24 hours to investigate and analyze changes in their transcriptome. The primary objective of this research was to accurately identify specific genetic alterations that occur when TAK960 is administered to cells. The findings of this study will provide critical insights into the underlying mechanisms of TAK960 and its associated biological effects, thus advancing our understanding of its potential as a therapeutic intervention for LUTS.